Celcuity Stock (NASDAQ:CELC)


ForecastChart

Previous Close

$49.47

52W Range

$7.58 - $63.06

50D Avg

$50.85

200D Avg

$21.74

Market Cap

$1.96B

Avg Vol (3M)

$1.48M

Beta

0.71

Div Yield

-

CELC Company Profile


Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

87

IPO Date

Sep 20, 2017

Website

CELC Performance


Latest Earnings Call Transcripts


Q2 22Aug 13, 22 | 8:14 AM
Q1 22May 16, 22 | 10:49 PM
Q4 21Mar 23, 22 | 9:28 PM

Peer Comparison


TickerCompany
CUECue Biopharma, Inc.
EVLOEvelo Biosciences, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
SRRKScholar Rock Holding Corporation
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks